This could be one of the most interesting findings in diabetes research in decades.
One remarkable finding was published in a clinical trial on June 22, 2025, in the New England Journal of Medicine: 83 percent of people with Type 1 diabetes who were treated with stem cell–derived therapy were able to stop using insulin for more than a year.
The treatment, known as VX-264, would function by replacing the body’s decimated beta cells the cells that make insulin.
How It Works
In one, scientists encapsulate lab-grown insulin producing cells and implant them in the body, where they spontaneously restore insulin production.
Why It Matters
It’s not a cure at least not yet. But for those whose daily lives are organized around insulin injections, this is an enormous leap. And encouragingly, "there were no reports of any serious side effects" from the treatment, according to lead researcher Dr. Trevor Reichman.
A Promising Future
This is the first time we have seen that we can restore safely and sustainably beta cell function. While the treatment is still in early days, the science is extremely promising.
This progress is an example of what is possible when research strives to get at the root cause of disease, and not merely at the symptoms. It also underscores a perennial truth: When the body is offered the proper instructions, it knows what to do to heal.
Share this Innovation with a friend or family member with diabetes
Ready to begin your health journey? Click Here
